Group 1 - The core announcement is about the exclusive sales agency agreement between the company's wholly-owned subsidiary, Kai Xi Hong Kong, and Beijing De Kai Pharmaceutical Technology Co., Ltd. for the sales and marketing of the company's anti-hair loss foam agent products in mainland China [1][2] - The collaboration aims to leverage the strengths and resources of both parties to enhance business development and product extension, achieving complementary advantages and collaborative growth [1][2] - The foam agent product is designed to have superior transdermal penetration and higher scalp accumulation compared to tinctures, with a formulation that does not contain propylene glycol, significantly improving tolerability and overall user experience [1] Group 2 - The partnership with De Kai Pharmaceutical is based on the high complementarity of resources and strategic synergy, aiming to fully utilize each other's strengths to jointly explore the market and achieve value co-creation [2] - The anti-hair loss foam agent product will access De Kai Pharmaceutical's nationwide multi-channel sales network, reaching over 25 million male chronic disease users and millions of active users monthly, significantly shortening the product's market introduction cycle [2] - This collaboration is expected to enhance user trust and medication adherence through De Kai's professional chronic disease management system, leading to a substantial increase in sales and brand influence, with a sales target of over 100 million RMB anticipated [2]
开拓药业-B就防脱泡沫剂产品订立独家销售代理协议